Buy Like Buffett
Watchlist

Mangoceuticals, Inc.

MGRX · Healthcare · $27173 mkt cap · FY2025 filings · · Shallow moat ·

Doesn't clear the bar

Shallow moat
Share / Embed this score
Embed this score

The five investor questions

50

2022–2025 (latest 4 aligned FYs; v3 window cap 5): revenue $8939 to $456021, increasing; diluted EPS -1.90 to -2.17, decreasing. Latest-filed diluted EPS remains usable for Business Trend, but an integer share-count change lacks enough evidence to confirm a comparable EPS basis; valuation growth therefore stays at 0%.

92

Median gross margin 56.9% over 4y, very stable.

0

Median ROIC -103.9%, above the 12% hurdle in 0% of years.

28

Net debt/EBITDA n/ax, interest coverage -174x.

48

Owner earnings changed trend unclear over up to the ten most recent annual observations.

Price vs. value if growth stopped today

A cautious baseline, not a price target: what the shares may support if normalized owner earnings simply hold steady.

Above value if growth stopped todayBelow value if growth stopped today
No price data
Not reported
Unavailable — insufficient owner-earnings data
Unavailable — insufficient growth-model data
$0.29
No price data

This zero-growth estimate assumes trailing owner earnings persist — unreliable for declining businesses. The recent FY revenue series does not trigger the three-consecutive-declines flag.

Among the current top-score group, the median current price is 243% above the zero-growth estimate across 49 of the current top 50 companies by Moat Score with both values.

Score records captured Oct 17, 2026.

Exactly which 50 companies?

FTNT, IBEX, META, MEDP, MSFT, GOOG, LULU, ANF, IDXX, TXRH, FHI, QLYS, FFIV, ADBE, LLY, MANH, CPRT, VEEV, RMD, GRMN, PCTY, EAT, UI, SSD, MNST, DOCS, LRCX, MCO, NTAP, NVDA, CORT, SFM, MPTI, ULTA, SN, ROL, CTAS, PAYC, IRMD, DECK, MORN, INTU, JKHY, TPR, LGCY, DAL, GWW, ISRG, MPWR, LOPE

Missing a usable price or zero-growth estimate: ANF.

Model details under moat-index@3.0.0: zero-growth multiple 11.1×, capped-growth comparison at no more than 18×; 9% discount rate; high-end growth 0% (capped at 4%) using min(5y revenue CAGR, 5y diluted-EPS CAGR), clamped to 0%–4%; maintenance capex uses min(capex, D&A); abstain when D&A is unavailable. This is a disclosed model range, not intrinsic value as fact.

5 years of fundamentals

The business, in plain English

Mangoceuticals, Inc. booked $456021 of revenue in FY2025 in the Healthcare sector and kept 54.9% of it as gross profit — a solid-margin business by that measure. After every other cost, −4526.8% of each revenue dollar reached the bottom line.

It earned −103.9% on invested capital in the latest filed year, FY2025. Across the full 3-year measurable filed record, median ROIC was −103.9%. Over the v3 recent window (3 measurable filed years), median ROIC was −103.9%. The Returns on Capital filter above scores it 0/100.

MGRX's latest filed year, FY2025, doesn't disclose total debt in a form the methodology can use, so current leverage is treated as unmeasured — never assumed to be zero.

Put together: Pricing Power is the strongest of the five filters (92/100) and Returns on Capital the weakest (0/100), which is how MGRX lands at 43/100 — a Shallow moat.

This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.

FY2021–FY2025 · 5 fiscal years, normalized from MGRX’s SEC filings

Sales, as filed$456021 FY2025
$0$500000202120232025
Revenue kept after cost of goods54.9% FY2025
0%25%50%202120232025
Standard ROIC or separately labeled Operating ROIC

Exact FY and FY-1 financing invested-capital inputs are required.

Exact FY and FY-1 financing invested-capital inputs are required.

Cash an owner could take out−$20.6M FY2025
−$20M−$10M$0202120232025

The explained ROIC gaps have filed inputs but no meaningful positive invested-capital denominator. Other gaps mean the item is not in the filings for that year. The series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.

Flagship explainer

How Mangoceuticals, Inc. makes its money

Mangoceuticals, Inc.'s filing does not supply enough comparable lines for a truthful flow chart — here's what is filed:

Table alternative
Filed lineValue% of revenueSource
$456021100%
  • 10-K · FY 2025Filing detailsAccession 0001493152-26-014478 · filed Apr 1, 2026
Cost of revenue$5442212%
  • 10-K · FY 2025Filing detailsAccession 0001493152-26-014478 · filed Apr 1, 2026
$25038655%
  • 10-K · FY 2025Filing detailsAccession 0001493152-26-014478 · filed Apr 1, 2026
−$18M−3954%
  • 10-K · FY 2025Filing detailsAccession 0001493152-26-014478 · filed Apr 1, 2026
Income before tax−$20.6M−4527%
  • 10-K · FY 2025Filing detailsAccession 0001493152-26-014478 · filed Apr 1, 2026
−$20.6M−4527%
  • 10-K · FY 2025Filing detailsAccession 0001493152-26-014478 · filed Apr 1, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0001493152-26-014478 · filed Apr 1, 2026
· event Dec 31, 2025 · retrieved Oct 17, 2026 · annual-row source set

Flagship explainer

What Mangoceuticals, Inc. owns — and owes

Mangoceuticals, Inc.'s filing tags don't support a full breakdown — here's what is filed:

Table alternative
Filed lineValue% of assetsSource
Total assets$16.1M100%
  • 10-K · FY 2025Filing detailsAccession 0001493152-26-014478 · filed Apr 1, 2026
Cash and equivalents$1.5M9%
  • 10-K · FY 2025Filing detailsAccession 0001493152-26-014478 · filed Apr 1, 2026
Stockholders’ equity$15.2M94%
  • 10-K · FY 2025Filing detailsAccession 0001493152-26-014478 · filed Apr 1, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0001493152-26-014478 · filed Apr 1, 2026
· event Dec 31, 2025 · retrieved Oct 17, 2026 · annual-row source set

Flagship explainer

What drives Mangoceuticals, Inc.’s return on equity?

ROE is five filed business factors multiplied together.

DuPont return on equity factor treeReturn on equity branches into tax burden, interest burden, operating margin, asset turnover, and the equity multiplier.Return on equity−142%Tax burden100%net income ÷ pretax incomeInterest burden114%pretax ÷ operating incomeOperating margin−3954%operating income ÷ revenueAsset turnover0.03×revenue ÷ average assetsEquity multiplier1.08×average assets ÷ average equityAs of 2025-12-31 · 3 SEC filing sourcesBuy Like Buffett · buylikebuffett.com
DuPont source inputs
InputValueFiscal yearSource
−$20.6MFY2025
  • 10-K · FY 2025Filing detailsAccession 0001493152-26-014478 · filed Apr 1, 2026
Income before tax−$20.6MFY2025
  • 10-K · FY 2025Filing detailsAccession 0001493152-26-014478 · filed Apr 1, 2026
Operating income−$18MFY2025
  • 10-K · FY 2025Filing detailsAccession 0001493152-26-014478 · filed Apr 1, 2026
$456021FY2025
  • 10-K · FY 2025Filing detailsAccession 0001493152-26-014478 · filed Apr 1, 2026
Ending assets$16.1MFY2025
  • 10-K · FY 2025Filing detailsAccession 0001493152-26-014478 · filed Apr 1, 2026
Beginning assets$15.4MFY2024
  • 10-K · FY 2024Filing detailsAccession 0001493152-26-014478 · filed Apr 1, 2026
  • 10-K · FY 2024Filing detailsAccession 0001641172-25-000085 · filed Mar 20, 2025
$15.2MFY2025
  • 10-K · FY 2025Filing detailsAccession 0001493152-26-014478 · filed Apr 1, 2026
$13.9MFY2024
  • 10-K · FY 2024Filing detailsAccession 0001493152-26-014478 · filed Apr 1, 2026
  • 10-K · FY 2024Filing detailsAccession 0001641172-25-000085 · filed Mar 20, 2025
Source: · event Dec 31, 2025 · retrieved Oct 17, 2026 · annual-row source set
Embed this chart

Flagship explainer

Where Mangoceuticals, Inc.'s cash went

Mangoceuticals, Inc.’s filing does not supply enough provenance-matched cash-flow lines for a truthful flow chart — here’s what is filed:

Table alternative
Filed lineValue% of cash from operationsSource
Cash from operations−$5.9M−100%
  • 10-K · FY 2025Filing detailsAccession 0001493152-26-014478 · filed Apr 1, 2026
Depreciation and amortization$1.1M19%
  • 10-K · FY 2025Filing detailsAccession 0001493152-26-014478 · filed Apr 1, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0001493152-26-014478 · filed Apr 1, 2026
· event Dec 31, 2025 · retrieved Oct 17, 2026 · annual-row source set

Curated 19-manager tier

Who reported holding Mangoceuticals, Inc.

Delayed public 13F reports for 2026-Q2—not live positions, trades, or recommendations.

0 holding0 exited0 not holding0/19 resolved19 not retrieved

Named manager positions and quarter-over-quarter changes
ManagerReported positionQuarter-over-quarterFiling accession
Abrams CapitalNot retrievedComparison not retrievedFiling not retrieved
Akre CapitalNot retrievedComparison not retrievedFiling not retrieved
Baupost GroupNot retrievedComparison not retrievedFiling not retrieved
Berkshire HathawayNot retrievedComparison not retrievedFiling not retrieved
Brave Warrior AdvisorsNot retrievedComparison not retrievedFiling not retrieved
Dodge & CoxNot retrievedComparison not retrievedFiling not retrieved
First EagleNot retrievedComparison not retrievedFiling not retrieved
FundsmithNot retrievedComparison not retrievedFiling not retrieved
Gardner Russo & QuinnNot retrievedComparison not retrievedFiling not retrieved
Gates Foundation TrustNot retrievedComparison not retrievedFiling not retrieved
Mairs & PowerNot retrievedComparison not retrievedFiling not retrieved
Markel / Markel-GaynerNot retrievedComparison not retrievedFiling not retrieved
Oakmark / Harris AssociatesNot retrievedComparison not retrievedFiling not retrieved
Pershing SquareNot retrievedComparison not retrievedFiling not retrieved
Polen CapitalNot retrievedComparison not retrievedFiling not retrieved
Sequoia / Ruane CunniffNot retrievedComparison not retrievedFiling not retrieved
Southeastern Asset ManagementNot retrievedComparison not retrievedFiling not retrieved
Tweedy, BrowneNot retrievedComparison not retrievedFiling not retrieved
Yacktman Asset ManagementNot retrievedComparison not retrievedFiling not retrieved

Position size uses shares and filed value from each manager’s 13F. Portfolio weight uses the eligible long-share filing denominator. Changes compare only with the immediately preceding calendar quarter.

Source: Filing source not retrieved · event Jun 30, 2026 · retrieved Oct 17, 2026

Flagship explainer

What Mangoceuticals, Inc. insiders reported

We could not retrieve insider activity for this rendering; no zero-activity claim is shown.

Unavailable: Form 4 activity could not be retrieved for this rendering.

Moat Score history

26 logged readings since Jul 18, 2026 · append-only, never rewritten

Moat Score over timeLast scored reading of each day, on the 0–100 scale43.4 / 100
0406080100WideNarrowShallowNo moatJul 18, 2026Oct 17, 2026

Breaks in the line mark methodology or normalizer upgrades — readings across versions aren’t compared, so a level shift there isn’t a change in the business.

Tier changesSame-methodology and same-normalizer crossings of the Wide / Narrow / Shallow bars

  1. Normalizer upgraded unstamped (version unknown)moat-xbrl-normalizer@1.1.0 — readings across versions aren’t comparedJul 26, 2026
  2. Methodology upgraded moat-index@2.0.0moat-index@3.0.0 — readings across versions aren’t comparedJul 23, 2026
  3. Methodology upgraded moat-index@1.2.0moat-index@2.0.0 — readings across versions aren’t comparedJul 20, 2026

Scores are logged append-only and never overwritten — this record cannot be reconstructed retroactively, which is exactly why it’s worth keeping.

Insider activity

Form 4 reports mix P/S market or private transactions with compensation-plan mechanics. Activity casually described as “insider selling” can include compensation mechanics; awards, tax withholding, and option exercises are shown by their exact filed class here, never collapsed into “Bought” or “Sold.”

These are disclosed filing facts and arithmetic aggregates, not a signal or verdict.

The insider-filing service is temporarily unavailable, so no partial or guessed answer is shown for MGRX.

Track record

How Mangoceuticals, Inc.’s moat rated in each of the years we can reconstruct from its filings — scored only on what was knowable at the time — and what its price and returns did afterward. The score never saw a price; the two are joined only in hindsight, for education, not as a signal.

Point-in-time scores 2023–2025, one methodology version · reconstructed from filings on file each Dec 31 — never with hindsight

Point-in-time Moat Score (dot colored by tier)Indexed price (total-return (dividends reinvested))Rated Wide-moat that year

How to read this: each dot is what the engine would have scored MGRX on that December 31; the line below is its total-return price path (dividends reinvested) in the years since.

0406080100WideNarrowShallowNo moatPoint-in-time Moat Score2050100Indexed price · log scale (2024 = 100)2023202420252026

Two tracks, one timeline: the score has its own 0–100 scale (top), the price its own 100-based scale (bottom) — never a shared axis. The price path is a total-return (dividends reinvested) index built from the same data the forward returns use; gaps in the score line are years with no reconstructed rating (see the table for why). The Table view carries every value.

What followed, in the years it rated Wide

In the reconstructed history shown, MGRX did not rate Wide-moat in any year, so there is no wide-moat track record to report. That absence is itself the honest answer — we don’t manufacture a comparison where the rating never earned one.

Healthcare context

#276 of 708 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

  1. #274MDAI SPECTRAL AI, INC.43.6Shallow moat
  2. #275TNON Tenon Medical, Inc43.4Shallow moat
  3. #277STXS STEREOTAXIS, INC.43.3Shallow moat
  4. #278STAA STAAR Surgical Co43.2Shallow moat

Compare MGRX with its nearest peers →All Healthcare companies on the Index →

Common questions about MGRX

Does Mangoceuticals, Inc. have an economic moat?
Based on its FY2025 SEC filings, the Moat Index scores Mangoceuticals, Inc. (MGRX) 43.4 out of 100 — a Shallow moat. The five questions behind that score begin at 20% each; if exactly one genuinely lacks data, the other four weights are renormalized and disclosed. revenue and EPS trend 50, pricing power 92, returns on capital 0, balance-sheet safety 28, capital allocation 48.
How has MGRX's Moat Score changed over time?
The record logs 26 readings since Jul 18, 2026; the latest reads 43.4 out of 100 (shallow moat). No tier changes on record yet. (Methodology or normalizer upgrades on Jul 20, 2026, Jul 23, 2026, Jul 26, 2026 re-based the score; readings across versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell MGRX. See the disclaimer.